Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Company Overview - Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) [3] - Vonoprazan is marketed in the U.S. as VOQUEZNA® for treating heartburn associated with Non-Erosive GERD and for the healing and maintenance of Erosive GERD [3] Upcoming Events - Members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:00 am ET [1] - The conference will take place from February 5-6, 2025, in New York, NY, and will include one-on-one meetings [2] - A live webcast and archived recording of the event will be available on the Phathom website for 90 days following the meeting [2]